Starkman, R Alibhai, S Wells, R A Geddes, M Zhu, N Keating, M M Leber, B Chodirker, L Sabloff, M Christou, G
...
Published in
Leukemia
The frailty index (FI) is based on the principle that the more deficits an individual has, the greater their risk of adverse outcomes. It is expressed as a ratio of the number of deficits present to the total number of deficits considered. We developed an MDS-specific FI using a prospective MDS registry and assessed its ability to add prognostic po...
Mohty, Mohamad Gautier, Jordan Malard, Florent Aljurf, Mahmoud Bazarbachi, Ali Chabannon, Christian Kharfan-Dabaja, Mohamed A Savani, Bipin N Huang, He Kenderian, Saad
...
Published in
Leukemia
The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histol...
Armenteros-Monterroso, Elena Zhao, Lu Gasparoli, Luca Brooks, Tony Pearce, Kerra Mansour, Marc R Martens, Joost H A de Boer, Jasper Williams, Owen
Published in
Leukemia
Subtype-specific leukemia oncogenes drive aberrant gene expression profiles that converge on common essential mediators to ensure leukemia self-renewal and inhibition of differentiation. The transcription factor c-MYB functions as one such mediator in a diverse range of leukemias. Here we show for the first time that transcriptional repression of m...
Jonas, Brian A Pollyea, Daniel A
Published in
Leukemia
Acute myeloid leukemia (AML) is associated with poor outcomes, especially in older patients in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein involved in the survival and maintenance of AML, and it is overexpressed in the leukemia stem cell population. Venetoclax is an oral BCL-2 protein inhibitor recently ap...
Nam, Jehyun Kim, Dong Uk Kim, Eungyoung Kwak, Bomi Ko, Min Ji Oh, Ah-Young Park, Bum-Joon Kim, Yea Woon Kim, AeRi Sun, Hokeun
...
Published in
Leukemia
A large body of evidence suggests that B-cell lymphomas with enhanced Myc expression are associated with an aggressive phenotype and poor prognosis, which makes Myc a compelling therapeutic target. Phosphodiesterase 4B (PDE4B), a main hydrolyzer of cyclic AMP (cAMP) in B cells, was shown to be involved in cell survival and drug resistance in diffus...
Pan, Jing Niu, Qing Deng, Biping Liu, Shuangyou Wu, Tong Gao, Zhiyong Liu, Zhaoli Zhang, Yue Qu, Xiaomin Zhang, Yanlei
...
Published in
Leukemia
Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from previous CD19 CAR T-cell therapy. Complete remiss...
Deb, Gauri Wingelhofer, Bettina Amaral, Fabio M R Maiques-Diaz, Alba Chadwick, John A Spencer, Gary J Williams, Emma L Leong, Hui-Sun Maes, Tamara Somervaille, Tim C P
...
Published in
Leukemia
The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL-translocated molecular subtype of AML. In AML, the use of drugs in combin...
Sidana, Surbhi Larson, Daniel P Greipp, Patricia T He, Rong McPhail, Ellen D Dispenzieri, Angela Murray, David L Dasari, Surendra Ansell, Stephen M Muchtar, Eli
...
Published in
Leukemia
This study evaluates newly diagnosed IgM (6%, n = 75/1174) vs. non-IgM light chain amyloidosis patients. IgM amyloid patients had lower light chains (12.5 vs. 22.5 mg/dL; p 1 organ involvement (31% vs. 44%, p = 0.02) was less common in IgM amyloidosis, while soft tissue and peripheral nerve involvement was more common. t(11;14) was less common (27%...
D'Agostino, Mattia Raje, Noopur
Published in
Leukemia
Despite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as one of the most promising target antigens. Chimeric antigen receptor (CAR) T-cell the...
Sauer, Martin G Lang, Peter J Albert, Michael H Bader, Peter Creutzig, Ursula Eyrich, Matthias Greil, Johann Gruhn, Bernd Holter, Wolfgang Klingebiel, Thomas
...
Published in
Leukemia
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
